- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07942792
Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)
Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study
The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).
Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).
Studientyp
Einschreibung (Geschätzt)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Consecutive patients referred to the Syncope Unit for severe unexplained syncope
Beschreibung
Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.
Exclusion Criteria: Non-severe syncope Definitions.
-
Unexplained syncope is defined as unexplained etiology or unexplained
-
Severe syncope is defined by the presence of one or more among the following:
-
Suspected life-threatening arrhythmias
-
Substantial impact on patient's quality of life (QoL)
- Frequent episodes
- Restriction of educational or occupational activities (including, but not limited to, unemployment)
- Restriction of social or daily-life activities, e.g. when syncope occurs while driving
-
High risk of clinically significant outcomes
- Syncope associated with major injuries/trauma, i.e. head injury or fractures
- Unpredictable syncope, i.e. without prodrome or identifiable triggers
-
Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure
-
Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope
-
-
Non-severe syncope is defined by the presence of one or more among the following:
- Sporadic (isolated) episodes without major impact on patient's QoL
- Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Unexplained syncope
Syncope Unit |
At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Zeitfenster: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Zeitfenster: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Assessment of number and costs of resource utilization associated to the clinical practices
Zeitfenster: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 09X605
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .